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Available online 18 September 2017Background: How have the long term outcomes of RA improved in the last decade?
Methods: Patients with DMARD naïve RA were randomized to 4 treatment strategies: 1. sequential DMARD
monotherapy, 2. step-up combination therapy, 3. initial combination therapy including prednisone or 4. includ-
ing infliximab. Treatment-to-target was aimed at DAS ≤ 2.4 (three-monthly calculations). Functional ability
(HAQ), radiologic damage progression (Sharp/vanderHeijde Score) and overall survival were reported.
Results: Patients in arms 3 and 4 showed earlier clinical improvement. Up to 50% achieved DAS-remission (b1.6),
up to 29% achieved drug free remission. Damage progressionwaswell suppressed (median after 10 years in com-
pleters 2 SHS points), functional ability approached normality (meanHAQ 0.6). Therewas no increasedmortality
(Standardized Mortality Ratio 1.16, 95% CI 0.92–1.46).
Conclusions: Early treatment determines early clinical improvement, treatment-to-target determines long term
outcomes. Prevention of relevant radiologic damage progression and disability, drug free remission and normal-
ized survival are realistic goals.. This is a©2017TheAuthors. Publishedby Elsevier Inc. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
For many years, rheumatoid arthritis has been associated with
prolonged, painful inflammation, progressively debilitating joint dam-
age and increased mortality. Therapies were often introduced late,
feared for potential side effects, and/or ineffective. However, from the
late 1990s, more disease modifying antirheumatic drugs (DMARD)
and drug combinations became available, and rheumatologists in the
Netherlands wondered which would be the best order to use them:
start with ‘cornerstone’methotrexate (MTX) and possibly other mono-
therapies and reserve combination therapy with prednisone or
infliximab for patients who did not respond sufficiently well, or start
with combination therapy and taper to monotherapy when possible?
This was addressed in a four-armed treatment strategy study (BeSt, ac-
ronym of the Dutch for ‘Treatment Strategies’), with arms 1 and 2
starting with MTX monotherapy (switching to or adding other
DMARD), and arms 3 and 4 starting with combination therapy, either
with prednisone (arm 3) or infliximab (arm 4) [1].
Previously, in the TICORA study it had been shown that functional
ability and radiologic damage progression outcomes were better if the
decision to intensify treatment was based on calculation of the Disease
Activity Score rather than on interview based evaluation of disease ac-
tivity [2]. Thus, in the BeSt study, three-monthly calculated DAS [3]
were used to determine whether treatment had to be intensified.n open access article underTo prevent over-treatment, since initial combination therapy
starters in theory could have responded well to monotherapy, also ta-
pering strategies were designed, if the treatment target of low DAS
was achieved for at least 6 months. When it was found that many pa-
tients had achieved DAS-remission even after tapering, from year 3 dis-
continuation of the last DMARD was introduced in the study protocol,
resulting in patients achieving drug free remission.2. Results
Of 508 patients with recent onset active (at least 6 of 66 joints swol-
len and 6 of 68 tender, and either an ESR of 28 or higher or a patient's
VAS for disease activity of 28 or higher) RA (ACR 1987 classification
criteria), 62% were still participating in the study after 10 years. Early
improvement had occurred more often in the initial combination ther-
apy arms [4]. But as a result of DAS-steered treatment adjustments, by
the end of year 1 and in subsequent years, similar percentages of pa-
tients across the four arms had low disease activity and DAS-
remission, and functional ability over time was similar and stable, ap-
proaching normality as reported in a 55-plus general population [5].
Discontinuation of all DMARD because of prolonged DAS-remission
had occurred in 26% of all patients without differences between the
strategy arms (p = 0.57). By the end of year 10, 11/109, 11/104, 12/
109 and 13/107 patients in arms 1–4 were still in drug free remission,
with a median duration of 25, 75, 38 and 68 months, respectively (p
= 0.27). Over time due to DAS steered treatment, patients in all arms
had gone through 4 treatment steps. Only 17% in arm 1, 11% in arm 2,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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which for patients in arms 3 and 4 meant they had tapered to mono-
therapy or drug free remission [6].
Disease flares defined by DAS increase to N2.4, occurred in most pa-
tients at least once, with a decreasing prevalence over time [7].Fig. 1. Flow diagram of the treatment strategies, showing required treatment intensification s
different patients may progress from one treatment step to the next over different time inte
Patients on infliximab (dosed at 8–weekly intervals) had additional DAS measurements one w
increased. Infliximab dose started with 3 mg/kg and, if DAS N 2.4, was stepwise be increased
Tapering of the dose could go in reverse order if three-monthly DAS calculations were ≤2.4 fo
mg/kg/day; Depomedrol, 3 gifts of 120 mg in week 1, 4 and 8; Gold 50 mg/week; HCQ, hyd
20 mg/day; MTX, methotrexate, dosages per week; Pred, prednisone 7.5 mg/day unless indicaOnly 25% of flareswere preceded by drug tapering. Flares were asso-
ciatedwith an increase in HAQ at the time of flare, but alsowith a higher
mean HAQ and more SHS progression over time.
Joint damage progression after 10 years of DAS-steered treatment
was low: median 2 points on the Sharp/van der Heijde score, withoutteps as long as three-monthly measured DAS remained N2.4. Note 1: In all strategy arms,
rvals, depending on individual DAS results at the three-monthly observations. Note 2:
eek before each next infusion. That DAS dictated if the infliximab dose would need to be
to 6 mg/kg, 7.5 mg/kg and finally 10 mg/kg (always rounded to the nearest hundred).
r at least 6 consecutive months. AZA, azathioprine 2-3 mg/kg/day; CSA, ciclosporin A 2.5
roxychloroquine 200 mg/day, IFX, infliximab, dosages once per 8 weeks; Leflunomide
ted otherwise; SSA, sulphasalazine 2000 mg/day.
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there had been statistically significantly less damage progression in
arms 3 and 4 [1,8]. Over time, the mean estimated SHS progression
was still statistically, but not clinically relevantly less in arm4 compared
to the other arms: 10.9, 8.4, 8.1, and 6.1 for strategies 1 to 4, respectively
(weighted GEE, P= 0.15 for overall comparison; P= 0.046 for strategy
1 vs. 4; P N 0.10 for other comparisons) [6].
Over 10 years follow up, there were a similar number of adverse
events in the strategy arms (74 per 100 patients' years, p= 0.159). Fre-
quencies of serious adverse events vary over time, without significant
differences between the arms [6]. Seventy-two patients died during
follow-up. Based on the general Dutch population, 62 would have
been expected, which results in a Standardized Mortality Ratio of 1.16
(95% confidence interval 0.92–1.46), without differences between the
strategy arms, indicating no increased mortality in the BeSt study
population.
3. Discussion
The BeSt study has shown that the long-term outcomes of patients
with RA have greatly improved in the last decades. The introduction of
new (combinations of) antirheumatic drugs has given rheumatologists
more options to treat patients better, intensifying and changing treat-
ment as long as disease activity is insufficiently suppressed. After
10 years of DAS-steered treatment there are few patients with clinically
relevant joint damage progression, many patients in clinical remission,
and even patients in prolonged drug free remission. Survival in this co-
hort was comparable to that of the general population. The debilitating,
destructive, deadly disease that rheumatoid arthritis was for so many
patients in the past, appears to have been tamed at last.
Given the design of the study, and the previous results of the TICORA
trial, it is very likely that the good long termoutcomes are due to contin-
ued three-monthly DAS calculations and treatment adjustments aiming
at DAS ≤ 2.4. ‘Treatment to target’ is now incorporated in daily practice
in most rheumatology clinics. To date, based on both theory and the re-
sults of the remission steered FINRA-Co study [9] and CAMERA study
[10], remission is the preferred target [11].
If rheumatoid arthritis is seen as a chronic, progressively worsening
disease, it is reasonable to compare the efficacy of therapies and treat-
ment strategies in terms of long term outcomes. The results of the
BeSt study show that the long term outcomes are less dependent on
the use of particular DMARDs than on treatment to target. However,Fig. 2.Mean functional ability over time (based on estimates of a linear mixed model).treatment of RA is not only a marathon, it is also a sprint. Early suppres-
sion of inflammation is important to alleviate symptoms and return pa-
tients to their normal way of life as much as possible. It will also help to
install hope and faith in the patient as well as the physician, motivating
both to continue following the treatment to target protocol [12]. Pa-
tients in arms 3 and 4 reported earlier functional improvement andFig. 3. Patient disposition over time (observed data, showing the percentage of total
number of patients included, not of total number of patients with data available at that
timepoint) for patients allocated to (A) sequential monotherapy, (B) step-up
combination therapy, (C) initial combination with prednisone and (D) initial
combination with infliximab. LDA, low disease activity (defined as DAS ≤ 2.4).
Fig. 4. Percentages of patients on various treatment steps over time for patients allocated to (A) sequential monotherapy, (B) step-up combination therapy, (C) initial combination with
prednisone and (D) initial combinationwith infliximab. *These lines in strategy arm 3 and 4 depict the number of patients on the initial treatment stepwho have tapered tomonotherapy
or discontinued all medication. Note 1: Outside protocol denotes patients who, although continuing DAS ≤ 2.4 steered treatment, did not use medications of the sort and/or at the time
required in the protocol. Note 2: Comparison of patients still on the initial treatment step at year ten: p b 0.001 for strategy arm 1 versus strategy arm 4; p b 0.001 for strategy arm 2
versus strategy arm 4; p = 0.002 for strategy arm 2 versus strategy arm 3; p = 0.038 for strategy arm 3 versus strategy arm 4; other comparisons not significant. Note 3: 47 patients
in drug-free remission at year 10 achieved this (i.e. achieved and maintained remission allowing to taper to drug-free) on the following treatment steps: methotrexate monotherapy,
13/47 (28%) (for all the initial treatment step in strategy arm 1 and 2); methotrexate and infliximab, 11 (23%) (for all the initial treatment step in strategy arm 4); methotrexate,
sulphasalazine and prednisone, 8 (17%) (for all the initial treatment step in strategy arm 3); methotrexate with sulphasalazine, 4 (9%); sulphasalazine monotherapy, 2 (4%);
leflunomide monotherapy, 2 (4%); methotrexate, ciclosporin A with prednisone, 2 (4%); methotrexate with sulphasalazine and hydroxychloroquine, 1 (2%); azathioprine with
prednisone, 1 (2%); outside protocol, 3 (6%). DMARD, disease-modifying antirheumatic drug; IFX, infliximab; MTX, methotrexate.
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Fig. 5. Percentage of patients with a flare per performed visit over time. Flare A: from any
DAS toDAS N 2.4with an increase inDAS of ≥0.6;minorflare B: fromDAS ≤2.4 toDAS N 2.4
with an increase inDAS of b0.6;majorflare B: fromDAS ≤ 2.4 to DAS N 2.4with an increase
in DAS of ≥0.6. Note, flares are defined from year 2 to year 10.
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larly in arm 4, more sustained work productivity in the first 2 years of
the study, compared to patients in arms 1 and 2 [14]. Early suppression
of inflammation is also associated with prevention of rapid radiologic
progression [15]. However, with continued treatment to target, in the
majority of patients radiologic damage progression was not associated
with a clinically relevant decrease in HAQ [16] (Figs. 1–6).
In conclusion, the BeSt study has shown that long term outcomes are
more dependent on treatment to target, resulting in little damage, nor-
malized ability and normal survival, but that the initial treatment deter-
mines the early response. Initial combination therapy with prednisone
or infliximab is most effective to achieve rapid suppression of disease
activity and can then often be tapered to monotherapy. Remission and
drug free remission can be achieved and appear realistic treatment tar-
gets. Since the end of the BeSt study, new treatment combinations and
antirheumatic drugs have been introduced for the treatment of RA.
New studies have been initiated, aiming at ever earlier treatment initia-
tion, and aiming at ever stricter remission outcomes. It is possible that
these endeavours will lead to the best outcome of all: a cure for RA.Fig. 6. Estimated radiographic damage (weighted generalized estimating equation),
during/after ten years of targeted treatment, with multiple medication adjustments
when low disease activity was not achieved or maintained, for the four treatment
strategies. Depiction of SHS estimates over time for the total BeSt population, as a result
of the weighted generalized estimating equation.Financial disclosure
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